Skip to Content

Dr Reddy's Laboratories Ltd 500124

Morningstar Rating
INR 6,155.15 +107.55 (1.78%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

500124 is trading at a 14% premium.
Price
INR 6,201.31
Fair Value
INR 9,472.93
Uncertainty
High
1-Star Price
INR 6,295.29
5-Star Price
INR 7,732.62
Economic Moat
Lbbp
Capital Allocation
Prjvctvn
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 500124 is a good fit for your portfolio.

News

Trading Information

Previous Close Price
INR 6,047.60
Day Range
INR 6,081.756,211.45
52-Week Range
INR 4,383.406,505.50
Bid/Ask
INR 0.00 / INR 0.00
Market Cap
INR 1.02 Tril
Volume/Avg
13,702 / 14,832

Key Statistics

Price/Earnings (Normalized)
20.06
Price/Sales
3.78
Dividend Yield (Trailing)
0.65%
Dividend Yield (Forward)
0.65%
Total Yield
0.65%

Company Profile

Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Large Core
Total Number of Employees
22,822

Competitors

Valuation

Metric
500124
TEVA
NVS
Price/Earnings (Normalized)
20.065.5114.20
Price/Book Value
3.852.114.24
Price/Sales
3.781.004.34
Price/Cash Flow
15.4110.9613.87
Price/Earnings
500124
TEVA
NVS

Financial Strength

Metric
500124
TEVA
NVS
Quick Ratio
1.800.540.88
Current Ratio
2.551.021.16
Interest Coverage
46.520.3910.94
Quick Ratio
500124
TEVA
NVS

Profitability

Metric
500124
TEVA
NVS
Return on Assets (Normalized)
15.57%6.70%12.15%
Return on Equity (Normalized)
21.70%39.00%27.10%
Return on Invested Capital (Normalized)
20.10%13.54%17.72%
Return on Assets
500124
TEVA
NVS
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ZTS
Zoetis Inc Class AMtpkvpxpSbdb$77.5 Bil
MKKGY
Merck KGaA ADRTjzxsmrkyGhfwxsr$76.9 Bil
HLN
Haleon PLC ADRKqmgjcppqWfj$38.4 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRCxmvkxhyjPknxy$15.9 Bil
VTRS
Viatris IncKqtgkmhfNfdlx$14.2 Bil
RDY
Dr Reddy's Laboratories Ltd ADRNdxlvqtghHhng$12.3 Bil
CTLT
Catalent IncHncychdwBqyqyq$10.2 Bil
PRGO
Perrigo Co PLCQvgnnlkTjy$4.4 Bil
CURLF
Curaleaf Holdings IncKglzwxcdCqqt$3.9 Bil
PBH
Prestige Consumer Healthcare IncWsqyjpwzbPbqlc$3.6 Bil

Sponsor Center